EA202091120A2 - Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы - Google Patents

Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Info

Publication number
EA202091120A2
EA202091120A2 EA202091120A EA202091120A EA202091120A2 EA 202091120 A2 EA202091120 A2 EA 202091120A2 EA 202091120 A EA202091120 A EA 202091120A EA 202091120 A EA202091120 A EA 202091120A EA 202091120 A2 EA202091120 A2 EA 202091120A2
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
nervous system
central nervous
disorders
thiazolinidone
Prior art date
Application number
EA202091120A
Other languages
English (en)
Other versions
EA202091120A3 (ru
Inventor
Ана Мария Гарсия Кольасо
Дэвид Джон Аугустус Экланд
Мария Пилар Пискуэта Лаланса
Марк Мартинель Педемонте
Original Assignee
Минорикс Терапьютикс С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Минорикс Терапьютикс С.Л. filed Critical Минорикс Терапьютикс С.Л.
Publication of EA202091120A2 publication Critical patent/EA202091120A2/ru
Publication of EA202091120A3 publication Critical patent/EA202091120A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Настоящее изобретение относится к 5-(4-(2-(5-(1-гидроксиэтил)пиридин-2-ил)этокси)бензил)тиазолидин-2,4-диону и новым стереоизомерам указанного соединения для применения в лечении расстройств центральной нервной системы (НС).
EA202091120A 2014-04-02 2015-04-01 Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы EA202091120A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14382130 2014-04-02

Publications (2)

Publication Number Publication Date
EA202091120A2 true EA202091120A2 (ru) 2020-08-31
EA202091120A3 EA202091120A3 (ru) 2020-12-30

Family

ID=50513194

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091120A EA202091120A3 (ru) 2014-04-02 2015-04-01 Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
EA201691997A EA035866B1 (ru) 2014-04-02 2015-04-01 Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201691997A EA035866B1 (ru) 2014-04-02 2015-04-01 Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных

Country Status (24)

Country Link
US (3) US9782395B2 (ru)
EP (2) EP3125888B1 (ru)
JP (2) JP6745726B2 (ru)
KR (1) KR102418167B1 (ru)
CN (1) CN106470991B (ru)
AU (1) AU2015239112C1 (ru)
CA (1) CA2943373C (ru)
CL (1) CL2016002508A1 (ru)
CY (2) CY1120454T1 (ru)
DK (2) DK3125888T3 (ru)
EA (2) EA202091120A3 (ru)
ES (2) ES2678046T3 (ru)
HR (2) HRP20180983T1 (ru)
HU (2) HUE039555T2 (ru)
IL (1) IL248037B (ru)
LT (2) LT3125888T (ru)
MX (1) MX2016012687A (ru)
NZ (1) NZ725492A (ru)
PL (2) PL3388064T3 (ru)
PT (2) PT3388064T (ru)
SG (1) SG11201608218QA (ru)
SI (2) SI3388064T1 (ru)
WO (1) WO2015150476A1 (ru)
ZA (1) ZA201607286B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2941562C (en) * 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
HUE039555T2 (hu) * 2014-04-02 2019-01-28 Minoryx Therapeutics S L 2,4-tiazolidindion származékok központi idegrendszer rendellenességeinek kezelésében
DK3548026T3 (da) 2016-12-01 2021-04-19 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-Hydroxyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolinidin-2,4-dion til behandling af ikke-alkoholisk fedtleversygdom
BR112019012972B1 (pt) * 2016-12-23 2023-04-18 Minoryx Therapeutics S.L Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos
WO2019234664A1 (en) 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
WO2019234689A1 (en) * 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
US20210228558A1 (en) * 2018-06-06 2021-07-29 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
JP2023525981A (ja) 2020-04-30 2023-06-20 ミノリックス セラピューティクス エセ．エレ． 肺炎症および間質性肺疾患を処置するためのレリグリタゾン
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
AU4104593A (en) * 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2002367154A1 (en) 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
WO2005016339A1 (en) * 2003-07-24 2005-02-24 Case Western Reserve University Methods for the treatment of parkinson's disease
AU2007227581B2 (en) * 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
JP2013514368A (ja) * 2009-12-15 2013-04-25 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 神経変性疾患を処置するための、ｐｐａｒ温存チアゾリジンジオンおよび組み合わせ物
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) * 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
CA2941562C (en) * 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
HUE039555T2 (hu) * 2014-04-02 2019-01-28 Minoryx Therapeutics S L 2,4-tiazolidindion származékok központi idegrendszer rendellenességeinek kezelésében

Also Published As

Publication number Publication date
PL3388064T3 (pl) 2021-07-19
IL248037A0 (en) 2016-11-30
JP6745726B2 (ja) 2020-08-26
WO2015150476A1 (en) 2015-10-08
LT3125888T (lt) 2018-07-10
US20180133202A1 (en) 2018-05-17
ZA201607286B (en) 2021-07-28
PT3388064T (pt) 2021-05-14
PL3125888T3 (pl) 2018-09-28
IL248037B (en) 2020-09-30
EA202091120A3 (ru) 2020-12-30
ES2872335T3 (es) 2021-11-02
DK3125888T3 (en) 2018-06-25
EA035866B1 (ru) 2020-08-21
JP2020117539A (ja) 2020-08-06
CN106470991A (zh) 2017-03-01
SI3388064T1 (sl) 2021-08-31
EP3388064B1 (en) 2021-03-10
JP2017511339A (ja) 2017-04-20
PT3125888T (pt) 2018-07-20
CL2016002508A1 (es) 2017-04-21
SI3125888T1 (en) 2018-08-31
HUE039555T2 (hu) 2019-01-28
US10179126B2 (en) 2019-01-15
EA201691997A1 (ru) 2017-02-28
SG11201608218QA (en) 2016-10-28
CA2943373A1 (en) 2015-10-08
CY1120454T1 (el) 2019-07-10
HRP20180983T1 (hr) 2018-08-10
CN106470991B (zh) 2020-07-31
BR112016022974A2 (pt) 2017-12-26
NZ725492A (en) 2023-06-30
ES2678046T3 (es) 2018-08-08
CY1124088T1 (el) 2022-05-27
AU2015239112B2 (en) 2020-05-07
KR102418167B1 (ko) 2022-07-08
LT3388064T (lt) 2021-05-25
HRP20210518T1 (hr) 2021-05-14
MX2016012687A (es) 2017-04-27
EP3125888A1 (en) 2017-02-08
DK3388064T3 (da) 2021-04-19
KR20160145639A (ko) 2016-12-20
CA2943373C (en) 2023-01-10
HUE055351T2 (hu) 2022-05-28
AU2015239112C1 (en) 2020-08-20
US9782395B2 (en) 2017-10-10
EP3388064A1 (en) 2018-10-17
US20160235729A1 (en) 2016-08-18
EP3125888B1 (en) 2018-05-23
AU2015239112A1 (en) 2016-11-10
US20190255032A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA202092442A3 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201790271A1 (ru) Ингибиторы гликозидазы
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201500362A1 (ru) Ингибиторы rho-киназы
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
HK1255438A1 (zh) 用於治療癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯並呋喃-2-基)甲基)丙烯酰胺
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201790209A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde
NZ630803A (en) Optically active pde10 inhibitor
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme